AQUESTIVE THERAPEUTICS INC

NASDAQ: AQST (Aquestive Therapeutics, Inc.)

Kemas kini terakhir: semalam, 1:15AM

3.46

-0.25 (-6.61%)

Penutupan Terdahulu 3.71
Jumlah Dagangan 3,360,585
Purata Dagangan (3B) 2,388,779
Modal Pasaran 434,879,456
Harga / Jualan (P/S) 9.58
Julat 52 Minggu
2.93 (-15%) — 6.74 (94%)
Tarikh Pendapatan 3 Nov 2026
Margin Keuntungan -162.33%
Margin Operasi (TTM) -114.13%
EPS Cair (TTM) -0.650
Pertumbuhan Hasil Suku Tahunan (YOY) -41.00%
Nisbah Semasa (MRQ) 6.12
Aliran Tunai Operasi (OCF TTM) -39.76 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -22.57 M
Pulangan Atas Aset (ROA TTM) -24.63%

AISkor Stockmoo

-1.7
Keuntungan lemah. Kecairan jangka pendek mencukupi. Aliran tunai negatif. info
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Pulangan atas Modal info NA
Nilai Pegangan info NA
Premium Risiko info NA
Penilaian Pasaran info NA
Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga turun. info
Daripada analisis teknikal AI kami terhadap carta. info NA
Corak Lilin info NA
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Berita terkini bercampur atau neutral. info
Sentimen Pegangan info NA
Orang dalam membeli bersih baru-baru ini. Harga di bawah harga belian orang dalam. info
Institusi bersih +3.33% daripada saham dalam pemfailan 13F terkini: 95 pemegang menambah, 78 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat +15.1% dari 31 Aug hingga 30 Oct 2026, 13.2 hari untuk tutup (FINRA). info
Persekitaran pasaran berhati-hati. info
Sektor mengatasi prestasi pasaran.
Tonggak-tonggak sependapat, jadi skor diperkukuh.
Perolehan sesaham turun naik. Mencatat kerugian dalam tahun-tahun kebelakangan. info
Di bawah garis aliran jangka sederhana. info
Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info
Harga hampir dengan paras sokongan. Paras sokongan dan rintangan menurun. info
Skor Akhir -1.70
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Bercampur Bercampur
Drug Manufacturers - Specialty & Generic (Global) Bercampur Bercampur
Stok Aquestive Therapeutics, Inc. Bercampur Menaik

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B Skor
AQST 435 M - - - -1.7
SUPN 6 B 27.84% - 1.59 -1.0
ANIP 2 B - 13.74 2.57 -0.1
COLL 783 M - 23.13 2.72 0.1
TKNO 480 M - - - 0.8
TLRY 279 M - - 0.200 -2.2

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Value
% Dimiliki oleh Orang Dalam 10.78%
% Dimiliki oleh Institusi 61.11%

Pemilikan

Nama Tarikh Syer Dipegang
Bratton Capital Management, L.P. 30 Sep 2026 9,810,958
Samsara Biocapital, Llc 30 Sep 2026 2,434,367
Rosalind Advisors, Inc. 30 Sep 2026 2,000,000
Blue Owl Capital Holdings Lp 30 Sep 2026 1,390,632
Nama Purata Belian ($) Purata Jualan ($) Jumlah Net Jumlah Nilai Bersih ($)
DALY RICHARD J 3.52 - 28,025 98,648
DAVIS MATTHEW W. - 3.55 -12,500 -44,360
Jumlah Keseluruhan Kuantiti Bersih 15,525
Jumlah Keseluruhan Nilai Bersih ($) 54,288
Purata Pembelian Keseluruhan ($) 3.52
Purata Jualan Keseluruhan ($) 3.55
Julat Insider ($)
3.52 (1%) — 3.57 (3%)
Nama Pemegang Tarikh Jenis Kuantiti Harga Nilai ($)
DAVIS MATTHEW W. Pegawai 12 Nov 2026 Jual (-) 7,197 3.57 25,693
DAVIS MATTHEW W. Pegawai 10 Nov 2026 Dibuang (-) 5,303 3.52 18,667
DALY RICHARD J Pengarah 10 Nov 2026 Beli (+) 28,025 3.52 98,648

Institusi

Pemilikan institusi: 65.06%

Kedudukan Pemegang Saham
Bertambah 95 11,250,763
Berkurang 78 7,172,973
Baharu 26 2,010,558
Dijual habis 20 1,892,405

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 29,318,686 13.2
15 Oct 2026 27,597,742 13.9
30 Sep 2026 28,748,212 13.1
15 Sep 2026 27,161,738 11.8
31 Aug 2026 25,478,782 7.2
14 Aug 2026 20,951,747 5.2

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

2 Positif 1 Negatif 8 Neutral
Tarikh Jenis Butiran
18 Nov 2026 Yahoo Finance Aquestive Therapeutics to Present at the Piper Sandler 38th Annual Healthcare Conference
WARREN, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, announced today that the management team will…
16 Nov 2026 Yahoo Finance Aquestive Therapeutics Eyes Needle-Free Allergy Treatment Launch Ahead of 2027 FDA Decision
Aquestive Therapeutics (NASDAQ:AQST) is preparing for a potential U.S. launch of its needle-free treatment for severe allergic reactions, with an FDA decision expected on March 16, 2027, CEO Dan Barber said at the 2026 Jefferies Global Healthcare Conference. The company’s lead product candidate, An…
09 Nov 2026 Yahoo Finance Aquestive Therapeutics to Present at the Jefferies Global Healthcare Conference
WARREN, N.J., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, announced today that the management team will…
06 Nov 2026 Yahoo Finance Aquestive Therapeutics Inc (AQST) (Q3 2026) Earnings Call Highlights: Revenue Dip Masks Anifilm ...
Aquestive Therapeutics Inc (AQST) navigates quarterly revenue fluctuations while advancing Anifilm toward a March 2027 FDA decision and securing a $10 million upfront licensing deal for Libervant.
05 Nov 2026 Yahoo Finance Aquestive Therapeutics to Present Data at the 2026 ACAAI Annual Meeting
WARREN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science, today announced that multiple oral and poster…
04 Nov 2026 Yahoo Finance Aquestive Therapeutics, Inc. Q3 2026 Earnings Call Summary
Moby summary of Aquestive Therapeutics, Inc.'s Q3 2026 earnings call…
04 Nov 2026 Yahoo Finance Aquestive (AQST) Q3 2026 Earnings Call Transcript
Anaphylm's March 2027 FDA date anchors a launch push backed by new funding.
04 Nov 2026 Yahoo Finance What Aquestive Therapeutics (AQST) Said on Its Q3 Earnings Call
Aquestive Therapeutics (NASDAQ:AQST) said it resubmitted its application for Anaphylm, an epinephrine sublingual film intended for severe allergic reactions, before the end of the third quarter and is preparing for a potential U.S. launch next year if the product receives Food and Drug Administratio…
03 Nov 2026 Yahoo Finance Aquestive Therapeutics (AQST) Reports Q3 Loss, Misses Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -30.00% and -31.51%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
03 Nov 2026 Yahoo Finance Aquestive Therapeutics: Q3 Earnings Snapshot
(AP) — Aquestive Therapeutics Inc. (AQST) on Tuesday reported a loss of $16…
03 Nov 2026 Yahoo Finance Aquestive Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Anaphylm resubmission accepted with PDUFA goal date of March 16, 2027 Anaphylm would be the first and only oral rescue medication for the treatment of severe allergic reactions, including anaphylaxis, if approvedCommercial preparations remain on track to support a potential U.S. launch of Anaphylm…
27 Oct 2026 Yahoo Finance Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that…
15 Oct 2026 Yahoo Finance Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027
FDA accepted the resubmission as complete and classified it as a Class 2 responsePrescription Drug User Fee Act (PDUFA) goal action date set for March 16, 2027Ex-U.S. strategy remains on track with Canadian NDS planned for Q4 2026 WARREN, N.J., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aquestive…
14 Oct 2026 Yahoo Finance Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film
Differentiated, portable buccal film would offer patients and caregivers an alternative to existing nasal and rectal seizure rescue treatments, a market opportunity that exceeds $450 million annually in the U.S.Patient market research demonstrated strong preference for buccal film, with 71% of…
29 Sep 2026 Yahoo Finance Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly
Appoints Rich Daly, a life sciences executive with more than 30 years of leadership experience across large pharmaceutical companies, emerging biotechnology companies, and public company boards, to its Board of Directors WARREN, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc.…
17 Sep 2026 Yahoo Finance Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable review timeline following its initial review of the resubmission WARREN, N.J., Sept. 17, 2026…
07 Sep 2026 Yahoo Finance Aquestive Therapeutics (AQST): Second Chance At Anaphylm Comes Into Focus
On August 11, Aquestive Therapeutics (NASDAQ:AQST) reported second-quarter 2026 results and said it remains on track to resubmit its Anaphylm epinephrine film to the FDA in the third quarter of 2026. That single sentence carries the whole story here. A company living and dying by one product…
01 Sep 2026 Yahoo Finance Aquestive Therapeutics to Participate in Upcoming September Investor Conferences
WARREN, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the…
Papar semua

Isyarat Terkini corak lilin dan silang EMA

▼ Silang maut 17 sesi lalu · 28 Oct
Jangka panjang · EMA 50/200
EMA 50 hari melintas ke bawah EMA 200 hari, tanda yang diperhatikan ramai bahawa arah aliran jangka panjang telah berubah menurun.

Persediaan Teknikal Sederhana

Susunan aliran
Kecerunan
Kemasukan
Dagangan
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga turun.
Sokongan terdekat: 3.31 – 3.62 · paras kukuh
Rintangan terdekat: 3.58 – 3.91 · paras kukuh

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Risiko / Ganjaran
TP1:
TP2:

Kerugian hingga SL berbanding keuntungan hingga setiap sasaran, dari EP. Nisbah 2 atau lebih biasanya dicari.

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda